151 related articles for article (PubMed ID: 24910381)
21. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.
Shaw BE; Apperley JF; Russell NH; Craddock C; Liakopoulou E; Potter MN; Wynn R; Gibson B; Pearce RM; Kirkland K; Lee J; Madrigal JA; Cook G; Byrne JL
Br J Haematol; 2011 Apr; 153(2):244-52. PubMed ID: 21382020
[TBL] [Abstract][Full Text] [Related]
22. [Clinical characteristics of acute graft-versus-host disease confined solely to gastrointestinal tract after allogeneic hematopoietic stem cell transplantation].
Feng R; Liu DH; Xu LP; Chen H; Zhang XH; Han W; Zhao T; Liu KY; Huang XJ
Zhonghua Nei Ke Za Zhi; 2010 Dec; 49(12):1028-31. PubMed ID: 21211361
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
24. Pretransplant conditioning with Campath-1H (alemtuzumab) in pediatric matched unrelated hematopoietic stem cell transplants: an institutional experience.
Nageswara Rao AA; Kumar R; Altaf S; Gourde JA; Rodriguez V; Khan SP
J Pediatr Hematol Oncol; 2012 Mar; 34(2):96-100. PubMed ID: 22146532
[TBL] [Abstract][Full Text] [Related]
25. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation.
Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H
Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374
[TBL] [Abstract][Full Text] [Related]
26. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
[TBL] [Abstract][Full Text] [Related]
27. Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD.
Jackson K; Curley C; Leach J; McLean A; Nakagaki M; Durrant S; Kennedy GA
Bone Marrow Transplant; 2011 Dec; 46(12):1579-80. PubMed ID: 21258421
[No Abstract] [Full Text] [Related]
28. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
[TBL] [Abstract][Full Text] [Related]
29. Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience.
De Jong CN; Saes L; Klerk CPW; Van der Klift M; Cornelissen JJ; Broers AEC
PLoS One; 2017; 12(10):e0187184. PubMed ID: 29073260
[TBL] [Abstract][Full Text] [Related]
30. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
31. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
[TBL] [Abstract][Full Text] [Related]
32. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
Wolff D; Roessler V; Steiner B; Wilhelm S; Weirich V; Brenmoehl J; Leithaeuser M; Hofmeister N; Junghanss C; Casper J; Hartung G; Holler E; Freund M
Bone Marrow Transplant; 2005 May; 35(10):1003-10. PubMed ID: 15806135
[TBL] [Abstract][Full Text] [Related]
33. [A comparison of clinical characteristics and prognosis of adult acute graft-versus-host disease between human leukocyte antigen- identical and -mismatched allogeneic hematopoietic stem cell transplantation].
Zhao X; Xu L; Liu D; Han T; Wang Y; Zhang X; Yan C; Chen H; Han W; Wang J; Zhao T; Li Y; Zhang B; Zhao X; Liu K; Huang X
Zhonghua Nei Ke Za Zhi; 2014 Jan; 53(1):35-9. PubMed ID: 24674726
[TBL] [Abstract][Full Text] [Related]
34. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
35. Tocilizumab for steroid refractory acute graft-versus-host disease.
Roddy JV; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC; Benson DM; Andritsos LA; Devine SM; Efebera YA
Leuk Lymphoma; 2016; 57(1):81-5. PubMed ID: 26140610
[TBL] [Abstract][Full Text] [Related]
36. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study.
Gorin NC; Isnard F; Garderet L; Ikhlef S; Corm S; Quesnel B; Legrand O; Cachanado M; Rousseau A; Laporte JP
Eur J Haematol; 2013 Oct; 91(4):315-21. PubMed ID: 23738686
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.
Barge RM; Starrenburg CW; Falkenburg JH; Fibbe WE; Marijt EW; Willemze R
Bone Marrow Transplant; 2006 Jun; 37(12):1129-34. PubMed ID: 16757974
[TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD).
Carella AM; Beltrami G; Scalzulli PR; Carella AM; Corsetti MT
Bone Marrow Transplant; 2004 Jan; 33(1):131-2. PubMed ID: 14566330
[No Abstract] [Full Text] [Related]
39. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
[TBL] [Abstract][Full Text] [Related]
40. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
